Shankar Biswas, Yashasvi Srivastava, Ayman Hamadttu. "Real-world comparison of cabozantinib versus regorafenib as second-line therapy for advanced hepatocellular carcinoma after first-line immune checkpoint inhibitors: A propensity score–matched analysis.." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.19_suppl.132